ConductScience.org, home

Paper41501375

The functional imperative in high-grade glioma.

Goh LSH and 5 others. Exp Mol Med, 2026. Cited by 2 papers, by iCite.

Cite this record

ConductScience Library. The functional imperative in high-grade glioma. Papers, record 41501375. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41501375

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
The functional imperative in high-grade glioma.
PubMed
Journal
Exp Mol Med
PubMed
Year
2026
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
2
iCite
Revised in PubMed
2026-10-05
PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Goh LSHLaura Shih Hui
2Thng DKHDexter Kai Haohttps://orcid.org/0000-0002-1325-4347
3Ang YLEYvonne Li En
4Ho DDean
5Toh TBTan Boonhttps://orcid.org/0000-0003-0292-6985
6Wong ALAAndrea Li Ann

Source PubMed

Download CSV of authors

Topics8

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
GliomaMajor topic
Brain NeoplasmsMajor topic
Precision MedicineMajor topic
Humans
Neoplasm Grading
Animals
Biomarkers, Tumor
Molecular Targeted Therapy

Source PubMed

Download CSV of topics

References114

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
117051156Glioma stem cells promote radioresistance by preferential activation of the DNA damage response.Nature2006https://conductscience.org/library/papers/17051156PubMed
230153097CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.J Clin Oncol2018https://conductscience.org/library/papers/30153097PubMed
338480922Intrathecal bivalent CAR T cells targeting EGFR and IL13Rα2 in recurrent glioblastoma: phase 1 trial interim results.Nat Med2024https://conductscience.org/library/papers/38480922PubMed
431327527An Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma.Cell2019https://conductscience.org/library/papers/31327527PubMed
519720927Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma.J Clin Oncol2009https://conductscience.org/library/papers/19720927PubMed
638664630A qualitative evaluation of factors influencing Tumor Treating fields (TTFields) therapy decision making among brain tumor patients and physicians.BMC Cancer2024https://conductscience.org/library/papers/38664630PubMed
739657679Patient-derived glioblastoma organoids as real-time avatars for assessing responses to clinical CAR-T cell therapy.Cell Stem Cell2025https://conductscience.org/library/papers/39657679PubMed
838390032Reassessing the efficacy of bevacizumab in newly diagnosed glioblastoma: A systematic review and external pseudodata-based analysis.Neurooncol Adv2024https://conductscience.org/library/papers/38390032PubMed
920472883mTOR signaling in glioblastoma: lessons learned from bench to bedside.Neuro Oncol2010https://conductscience.org/library/papers/20472883PubMed
1036567957Upfront BRAF/MEK inhibitors for treatment of high-grade glioma: A case report and review of the literature.Neurooncol Adv2022https://conductscience.org/library/papers/36567957PubMed
1130018133Selection of Protein Kinase Inhibitors Based on Tumor Tissue Kinase Activity Profiles in Patients with Refractory Solid Malignancies: An Interventional Molecular Profiling Study.Oncologist2018https://conductscience.org/library/papers/30018133PubMed
127001230Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery.N Engl J Med1980https://conductscience.org/library/papers/7001230PubMed
1335849035Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: A phase III randomized clinical trial.Neuro Oncol2023https://conductscience.org/library/papers/35849035PubMed
1433414553Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts.Nat Genet2021https://conductscience.org/library/papers/33414553PubMed
1516697959Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines.Cancer Cell2006https://conductscience.org/library/papers/16697959PubMed
1634250400High-Throughput Drug Screening and Multi-Omic Analysis to Guide Individualized Treatment for Multiple Myeloma.JCO Precis Oncol2021https://conductscience.org/library/papers/34250400PubMed
1720129251Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1.Cancer Cell2010https://conductscience.org/library/papers/20129251PubMed
18216819Quality and duration of survival in glioblastoma multiforme. Combined surgical, radiation, and lomustine therapy.JAMA1979https://conductscience.org/library/papers/216819PubMed
1923333277Patient-specific orthotopic glioblastoma xenograft models recapitulate the histopathology and biology of human glioblastomas in situ.Cell Rep2013https://conductscience.org/library/papers/23333277PubMed
2034422657Uncovering Spatiotemporal Heterogeneity of High-Grade Gliomas: From Disease Biology to Therapeutic Implications.Front Oncol2021https://conductscience.org/library/papers/34422657PubMed

See all 114 referencesDownload CSV of references

Cited by3

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.

PMIDTitleJournalYearIn PapersSource
42882426Stromal Remodeling of the Cytokine Secretome Reveals a Chemokine Core Across Breast Cancer and Glioma 3D Cell Culture Models.Cells2026https://conductscience.org/library/papers/42882426PubMed
42591582miR-506-5p targets MAPK7 to impede glioma growth and invasion through suppressing epithelial-mesenchymal transition and matrix metalloproteinases.Transl Cancer Res2026https://conductscience.org/library/papers/42591582PubMed
42042543Molecular Oncodiagnostics in Precision Oncology: Integrating Tumor Transcriptomics, Patient Pharmacogenetics, and Ex Vivo Chemoresistance Testing to Improve Individual Chemotherapy Response.J Pers Med2026https://conductscience.org/library/papers/42042543PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41501375

GET https://conductscience.org/api/papers/v1/41501375/references?page=2